INTC goes into its Q1 2026 results on May 13 carrying a historic run-up that has left the analyst consensus far behind.
The price action is the story. INTC has gained 35% in a single week and more than doubled over the past month, closing at $129.44 on Monday. That compares to a mean analyst price target of $84.43 — a gap that suggests the market has already priced in a recovery story that most of Wall Street has yet to endorse. Peers caught the same bid: AMD gained 26% on the week and QCOM added 24%, so broad semiconductor tailwinds explain part of the move. But INTC's acceleration is steeper, and the RSI has climbed to a stretched 85 — close to overbought territory. Options traders are leaning cautious: the put/call ratio is 1.11, above its recent average of 1.02, and near its 52-week high of 1.13. That is only about 1.4 standard deviations above the mean, so hedging demand is elevated without being extreme — investors are buying insurance but not panicking.
Short sellers are not the driver here. Short Interest is modest at 2.8% of free float, with no dramatic trend — it has been range-bound in the 115–142 million share band since April. The ORTEX short score of 30.7 is well below the 50 midpoint, confirming this is not a heavily shorted name under pressure. Borrow is cheap at 0.48% cost to borrow, and availability is ample, meaning there is no meaningful squeeze dynamic at play. The 10% month-on-month rise in short shares is gradual rather than urgent — more opportunistic positioning against a rallying stock than a committed bear thesis.
The analyst community is conspicuously cautious compared to where the stock is trading. Post the last earnings on April 23 — when INTC jumped 26% in a single day and extended to a 45% five-day gain — most firms simply raised targets rather than upgraded. JPMorgan moved to $45 (Underweight), Morgan Stanley to $73 (Equal-Weight), and UBS to $83 (Neutral). Even the most constructive recent action — Tigress Financial lifting to $118 and Keybanc to $110 (both Buy) — sits well below the current $129.44 price. The factor scores tell an interesting tale alongside this: EPS momentum ranks in the 99th percentile on a 30-day basis, and the analyst recommendation divergence also sits at the 99th percentile, signalling that positive earnings revisions are running far ahead of rating upgrades. Bulls see a genuine AI and foundry transformation story backed by a strong pipeline. Bears point to intense competitive pressure in microprocessors, the structural challenge of the x86 architecture, and a normalized net income of $5.6B that still has to support capital expenditure running at $15.6B annually.
The May 13 print therefore tests a specific question: whether Intel's operational progress on the foundry transformation — and any guidance on AI-related revenue — is strong enough to justify trading at a meaningful premium to the consensus target, or whether the market's enthusiasm since April 23 has run ahead of what the numbers can sustain.
See the live data behind this article on ORTEX.
Open INTC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
